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Introduction
The rare incidence and heterogeneousnature of
soft tissue sarcomas (STS) are formidable barriers
to the conduct of large randomised controlled trials
(RCTs). A search of computer databases, using a
Cochrane optimal search strategy 1966–1996,
yielded less than 100 RCTs investigating the
management of bone and soft tissue sarcomas
(Bramwell 1997, Proceedings5th Annual Cochrane
Colloquium – unpublished data). Of these, approxi-
mately 40 are relevant to the management of
advanced/metastatic STS, but some report on
treatments that are no longer used. Thus, recom-
mendationsfor management of advanced STS,
in a substantial proportion of situations, have to
be based on findings from observational/phase II
studies and/or clinical consensus, as better evidence
doesnot exis t.
Definition of advanced sarcoma
STS arise from mesenchymal tissue which is
ubiquitousin the body. In contras t with many
cancers that relate to a particular site (e.g. breast)
and that display a limited number of characteristic
histologies (e.g. adenocarcinoma), STS are markedly
heterogeneousin location and his tology, and thus
in behaviour. Advanced STS may be defined under
two headings: (1) locoregional disease; (2) distant
metastases.
(1) Locoregional disease
There are three main situations in which locoregional
disease becomes difficult to control, and may be life-
threatening in the absence of distant metastases.
Curative local treatment is impossible because of location
For some primary STS, involvement of vital
organsor s tructureslimitsthe potential for curative
treatment. Distant metastasis may still be the
commonest cause of death, but in a significant
minority uncontrolled local tumour may be fatal.
In the head and neck, retroperitoneum, paraspinal
regions and visceral sites (bowel, uterus) tumours are
often locally advanced at presentation, and/or loco-
regional relapse occurs frequently. The prognosis of
primary tumours arising in such vital organs as the
heart and great vessels, lung, liver, brain and spinal
cord iseven more ominousand mos t are ultimately
fatal.
Recurrence after surgery and radical radiotherapy
Many of the tumours(e.g. retroperitoneal, head and
neck, etc.) mentioned in the preceding section
eventually fall into thiscategory, aswell asextremity
sarcomas recurring in amputation sites. Curative
optionsare limited for radiation-induced s arcomas
in central locations. Desmoid tumours (aggressive
fibromatosis), although they do not metastasise,
have a high rate of recurrence that may be debili-
tating and cause the death of a small minority of
patients.
1
(2) Presence of lymph node metastases
Although rare in adult STS, lymph node metastases
denote advanced disease. As well as being a marker
of poor prognosis, categorised as stage IV disease
by UICC staging,
2 their presence particularly at
geographically separate sites complicates local
management.
Distant metastases
In common with many cancers, STS can disseminate
widely, and most patients with distant metastases
have incurable disease. Evidence for the contention
that, for some patients, aggressive treatments can
eradicate metastatic sarcoma, prolong life and cure a
minority of patientswill be examined.
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Presentation ‘de novo’ with advanced STS
Based on data from the National Cancer Institute
Surveillance, Epidemiology and End Results (SEER)
database 1986–1990, the estimated annual incidence
of adult STS (excluding Kaposi sarcoma) is around
four to five per 100000 population, which represents
less than 1% of all malignancies.
3
Statistics on the incidence of metastases at
presentation of STS, and subsequent local and
regional failure ratesare provided in reportsfrom a
large American cancer registry. Lawrence et al.
4
described results of a Pattern of Care Survey by the
Committee on Cancer of the American College of
Surgeons(CCACS) for the years1977–1978 and
1983–1984. ThisCCACS databas e wasexpanded to
become a joint project with the American Cancer
Society, termed the National Cancer Data Base
(NCDB), and Pollak et al.
5 reported updated
information in 1996. Approximately 23% of adults
with STS had metastases at presentation and this
varied from 18 to 35% by primary site (Table 1).
Lung was the most frequent single site, but only
represented a third of metastatic lesions (Table 2).
Development of advanced STS after primary treatment
Data from the CCACS and NCDB reports, on
patientspres enting without metas tas esand followed
for more than 5 years, showed a locoregional failure
rate of around 19%, and distant failure in 18–20% of
cases, which also varied by primary site (Table 3).
The CCACS and NCDB databases are retro-
spective and depend on acute care hospitals volun-
tarily reporting cases to a computerised cancer
registry. Central pathology review was not performed
and staging was a composite of clinical and
pathological stages. Data on incidence and sites of
recurrence were missing for many cases, limiting the
reliability of conclusions based on a proportion of
patients. Although results from the databases of
single institutions may be distorted by referral pat-
terns, they can provide in depth data on outcomes.
Pisters et al.
6 used a prospectively established
database at Memorial Sloan Kettering Cancer
Table 3. Treatment failure of soft tissue sarcoma
% Recurrence
Study (Reference) Year Number of patients Sites Locoregional Metastases
CCACS (4) Not stated 1209
* All 19.5 17.9
NCDB (5) 1988 833
* All 18.8 19.7
Heart, mediastinum, pleura 8.2
Peripheral/autonomic nervous
system
28.6
Peritoneum/retroperitoneum 12.3
Connective tissue/subcutaneous/
other soft tissue
22.9
*Subset patients with adequate data.
Table 1. Presentation with metastatic soft tissue sarcoma
Study (Reference) Year Number of patients Sites % Metastases
CCACS (4) 1977–78 2355 All 23.4
1983–84 3457 All 23.3
NCDB (5) 1988 3500 All 20.5
1983 4252 All 20.9
940 Heart, mediastinum, pleura 35
108 Peripheral/autonomic nervous system 21
528 Peritoneum/retroperitoneum 35
2676 Connective/subcutaneous/other soft tissue 18
Table 2. Sites of metastases* of soft tissue sarcoma
% Patients by metastatic site
Study (Reference) Year Lung Bone Liver Other
CCACS (4) 1977–78 33 23 15 26
1983–84 34 24 16 24
*Data not available in NCDB report.
44 V. H. C. BramwellCentre (MSK) to analyse prognostic factors and
outcome for 1041 patientswith localis ed STS of
the extremities. The MSK database spanned 1982–
1994, and the median follow-up time for all patients
was 3.95 years. (The MSK database has been used to
analyse many different questions relating to STS.
For several reports quoted in this chapter, the years
spanned in the analyses and patient numbers differ
between studies, but all are using a similar data set).
Although 181 patients(17%) developed local recur-
rence, in the absence of metastases most could be
salvaged by further locoregional treatment. Two
hundred and twenty-four patients(22%) developed
distant metastases within a median time of 13
months. Sixty-eight had distant metastasis that
occurred synchronously with, or subsequent to, a
local recurrence. In the Cox multivariate analysis,
relative risk (RR) of distant recurrence was greater
for large tumour size (5–10cm, RR 1.9; >10cm,
RR 1.5), presentation with locally recurrent disease
(RR 1.5), deep tumour location (RR 2.5) and high
grade (RR 2.5). With other prognostic factors
balanced in the regression analysis, histological
subtypes leiomyosarcoma (RR 1.7) and liposarcoma
(RR 0.64) were adverse and favourable prognostic
factors, respectively.
The French Federation of Cancer Centres
7 has
established a cooperative database with collegial
pathology review. Between 1980 and 1994, 1240
patientswith localis ed STS were included, not only
extremity STS (731 patients) but 80 head and neck
sarcomas, 232 of the trunk wall and 182 internal
trunk cases (retroperitoneum, abdominal cavity and
pelvis). By multivariate analysis, unfavourable char-
acteristics predicting the development of distant
metastases were high grade (RR 7.8), size >10cm
(RR 2.02) bone or neurovascular invasion (1.5) and
deep location (1.47).
Clinical features/evolution of advanced
sarcoma
Prognostic factors/outcome for patients with
advanced STS
Localised sarcomas at specific sites
STS occurring at certain sites are highly likely to
be advanced at presentation or to progress locally
(with or without metastases) because of anatomic
constraints on treatment. These problems are
reflected in 5-year survival data by site from the
NCDB database: 14.3% for heart/mediastinum/
pleura; 67.1% for peripheral/autonomic nervous
system; 46.1% for peritoneum/retroperitoneum;
and 67.4% for connective/subcutaneous/other soft
tissue locations.
There is increasing evidence that mesenchymal
tumours of the gastrointestinal tract, previously
labelled leiomyosarcomas, are a distinct clinicopatho-
logical entity.
8 Now classified as gastrointestinal
stromal tumours (GIST) they are thought to arise
from the interstitital cell of Cajal, an intestinal
pacemarker cell.
9 These cells exhibit both smooth
muscle and neural differentiation, and express the
hematopoietic progenitor cell marker CD34, aswell
asthe c-kit tyrosine kinase.
10 These tumours have a
high recurrence rate.
11 Ng et al. found that only 13/
132 (10%) of patientswith initial complete res ection
were free of disease at a median follow-up of
68 months. Factors significantly associated with
improved survival after relapse were initial disease-
free interval of  18 months, recurrences either
isolated to the peritoneal cavity or within the liver,
or complete resection of peritoneal recurrence or
liver metastases.
12 Similarly, with a median follow-
up of 24 months(range 1–175), DeMatteo et al.
13
reported recurrencesin 32 (40%) of 80 patients
undergoing complete resection of GIST, with a
5-year disease-specific survival of 54%. Survival was
predicted by tumour size but not microscopic
marginsof res ection.
Lymph node metastasis
The MSK database
14 has also been used to examine
the prevalence and natural history of lymph node
metastasis in adult STS. Of 1772 patients with STS
at all sites registered between 1982 and 1991, 46
(2.6%) showed lymph node metastases. Two large
literature reviewsdocumented a higher incidence:
9.1%
15 and 10.8%,
16 but may have suffered from a
reporting bias. In the MSK data set, tumour types
with the highest prevalence of lymph node metas-
tases were angiosarcoma 5/37 (13.5%), embryonal
rhabdomyosarcoma 12/88 (13.6%) and epithelioid
sarcoma 2/12 (16.7%). Although most of the
remaining cases were in leiomyosarcoma and malig-
nant fibroushis tiocytoma (MFH), thisonly repre-
sented incidence rates of 2.5 and 2.6% in each of
these subtypes. In all but one case, the primary
tumours were high grade sarcomas. Median survival
from the time of primary diagnosis was 30 months
and from the time of lymph node metastasis was 12.8
months. By univariate analysis, visceral location of
the primary, histological type MFH and limited
surgery for lymph node metastases were found to
confer a poor prognosis. These findings were based
on small numbers with short follow-up and should
be interpreted with caution.
Distant metastases
The 5-year survival data for patients with stage IV
disease at presentation was similar for both CCACS
and NCDB studies, around 19%. The CCACS
study also analysed the results of salvage therapy by
site of recurrence, reporting 5-year survival rates of
60.5, 20.8 and 9.8% for patientswith local relaps e
only, patients with lung metastases only and patients
with multiple metastatic sites.
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17 used the MSK database 1992–
1996, comprising 994 adult patients with primary
extremity STS, to analyse survival of patients with
distant metastasis. The median follow-up was 33
months, during which 230 (23%) patients developed
metastases. The lungs were the first site of metastasis
in 169 patients (73%), with soft tissues (10%) being
the next most common site. The median survival
after diagnosis of metastases was 11.6 months, and
actuarial survival at 2 years was 28% (median follow-
up 10 months). By multivariate analysis, adverse
prognostic factors for post metastasis survival were
unresectable metastatic disease (RR 2.3; P¼0.0001),
local recurrence with or before distant metastasis,
(RR 2.0; P¼0.01), disease-free interval <1 year (RR
1.4; P¼0.03) and age >50 years(RR 1.4; P¼0.05).
Other factors such as metastatic disease limited to
one lung and characteristics of the primary tumour
had no significant effect on outcome after first
metastasis.
Common clinical problems/causes and modes of death
Locoregional STS
Given the diversity of possible primary sites, locally
advanced incurable STS can present with a large
range of symptoms and signs. Most of these are the
consequence of a locally expanding mass causing
pressure on, or destruction of, adjacent tissues. This
damage to soft tissues may cause pain, ulceration and
bleeding; in bone/jointsit can lead to pain, fracture,
joint effusion, loss of function; and in nerves/spinal
cord result in pain and loss of function (numbness or
muscle weakness). Within the body cavities a variety
of effects may be seen, such as bleeding, perforation
or obstruction of the gastrointestinal and genitour-
inary tracts; and effusions (pleural, pericardial),
bleeding and respiratory obstruction caused by
intrathoracic STS. Causes of death associated with
uncontrolled locoregional sarcoma usually relate to
catastrophic bleeding, infection, obstruction (most
commonly bowel or renal) and thromboembolic
disease.
Distant metastases
The lungs and pleura are the commonest sites of
metastasis from STS. Symptoms may not appear
until lung metastases reach a substantial size and/or
number. Among the other factorsdetermining the
appearance of symptoms are patient activity level,
pulmonary reserve, and location of the metastases.
Effusions commonly develop in conjunction with
pleural based metastases. Death is usually due to
respiratory failure and/or infection.
Retroperitoneal and visceral (gastrointestinal,
genitourinary) STS often metastasise to the liver,
and hepatic metastasis is occasionally seen from
other primary sites. Early symptoms are nausea,
fatigue, satiety followed by pain, abdominal swelling
and jaundice, ultimately leading to hepatic failure.
GIST, and some other intra-abdominal retroperito-
neal tumours, may disseminate widely within the
abdomen. Patientswith extens ive intra-abdominal
disease may be remarkably free of symptoms for long
periods. Eventually patients succumb to subacute/
acute obstruction or perforation/bleeding.
Bone metastases occur infrequently, being less
commonly associated with STS than with bone
sarcomas. Pain and fractures are the commonest
complications but skeletal metastases are rarely a
direct cause of death. Central nervous system meta-
stases are rare, but brain metastases may present with
headachesor central neurological deficits . Spinal
cord compression may be seen from epidural
metastases, collapse of vertebrae due to bone
metastases or locoregional invasion by STS.
Symptomatic and supportive care measures used
to deal with complicationsof uncontrolled local or
metastatic tumours, vary by site and are beyond the
scope of this article.
Treatment of soft tissue sarcomas
Surgery
Debulking of primary tumour
Partial removal (debulking) of locally recurrent STS
israrely beneficial, es pecially if the recurrence isin
an irradiated field. There is a risk of rapid progres-
sion/local recurrence in the operative site. A rare
exception might be made for a slowly evolving low
grade STS, especially within the abdominal cavity, or
borderline tumours such as fibromatoses. Debulking
associated with radiotherapy and/or chemotherapy is
discussed below.
Resection of metastases
Pulmonary. It isgenerally accepted that, in s elected
cases, pulmonary metastatectomy is potentially
curative, although thishasnever been confirmed in
a RCT. Most patients with isolated pulmonary
metastases can be considered for metastatectomy.
In a review of the English language literature
1978–1994, comprising 12 case series totalling
697 patients, Frost
18 identified three pretreatment
adverse prognostic factors: (1) tumour doubling time
<40 days; (2) >4 nodules; (3) disease-free interval
<12 months. Incomplete resection is associated with
a poor outcome. Patientswith medias tinal lympha-
denopathy and/or tumour-related pleural effusion
should not be considered. Frost found the 5-year
survival rates to range from 15 to 35% for first time
pulmonary metastatectomy and from 12 to 52% for
reoperations, with a median value of 25% in all
patientsundergoing res ection.
Other sites. Therapeutic lymphadenectomy with
curative intent wasperformed in 31 of 46 cas esof
46 V. H. C. BramwellSTS with lymph node metastases registered in the
MSK database described earlier.
14 Median survival
for these patients was 16.3 months and 46% survived
5 years. The 15 patients not treated by lymphade-
nectomy did poorly with a median survival of 4.3
months (range 1–32). This is a biased comparison,
as fitter patients may have been selected for surgery.
If technically feasible, the primary tumour is con-
trolled and there are no distant metastases, radical
lymphadenectomy islikely to produce good pallia-
tion with the potential for cure.
Investigators from MSK have reported their
experience of liver resection in 96 patients with
hepatic metastases from non-colorectal, non-
neuroendocrine cancers, 41 of whom had STS.
19
Median survival after hepatic resection of STS was
31 months, and there was one 5-year survivor.
Disease-free interval >36 months before detection
of liver metastases, complete resection and pri-
mary tumour group (genitourinary cancers>
STS> gastrointestinal cancers) were predictors of a
significantly better survival, by multivariate analysis.
In a prospective protocol of debulking surgery,
Karakousis et al.
20 included 72 consecutive patients
with STS disseminated within the abdomen.
Median survival from first exploratory surgery was
23 monthsfor the 46 patients(64%) in whom com-
plete resection was possible. Median survival times
for grade I, II, II tumourswere 35.4, 17.5, 14.5
months, respectively (P<0.01) and for patients
undergoing complete resection, medial survival was
better for completely resected cases with a disease-
free interval >36 months.
The incidence of brain metastases from STS
islow, and varieswith his tology from 1 to 8%.
Incidence is increasing because, it is suggested, of
prolonged survival associated with improved sys-
temic control of disease. Further, many chemother-
apeutic agentsfail to cros sthe blood–brain barrier.
21
In a case series of 21 patients with brain metastases
from a variety of bone and soft tissue sarcomas,
22
median survival after craniotomy was 11.8 months.
No patient survived 5 years, but six were alive at the
time of reporting, the longest surviving 25 months.
As for lung and liver metastases, complete removal is
critical for long-term survival.
Radiotherapy
Alternative radiotherapy techniques for
locoregional recurrence
Most patients who develop inoperable local recur-
rence have previously received radical radiation to
doses in excess of 6000cG (or lower doses within the
abdomen but still close to tolerance of normal
tissue). Those who have not should be considered
for radical locoregional radiotherapy which, even
in the presence of bulky sarcoma, may produce
long-term control.
23 Additional palliative irradiation
may be possible at previously irradiated sites to
relieve symptoms such as pain, bleeding, loss of
function, etc. The benefitsof treatment vers usthe
long-term radiation complications must be assessed
in the context of the life expectancy of the patient.
Brachytherapy has been successful in controlling
STS recurrence after previouss urgery and external
beam radiation (EBR), although most of the reported
experience relatesto extremity s arcoma.
24 High
linear energy transfer (LET) radiation therapy
s uch asneutronsproduceshigh ratesof local
control in patientswith macros copic res idual STS
and unresectable tumours <10cm,
25 but at a cost
of substantial toxicity. Increasing use of conformal
therapy and light ion beam therapy, combining
the dose distribution advantages of protons with
the biological propertiesof high LET particles ,
26 may
improve results. Intra-operative irradiation, which
permitsdelivery of a large radiation dos e directly to
the tumour mass while sparing normal tissue such
as bowel, has produced promising results in retro-
peritoneal STS
27 when used in combination with
surgery and EBR. Data in this area are sparse, and
as current fiscal realities limit availability of these
costly machines and facilities, treatment should be
given only in a trial setting.
Radiotherapy for metastases
For STS metastases at many sites, EBR may be an
effective palliative treatment. It should be reserved
for symptomatic disease, or involvement of sites
likely to cause severe complications, such as incipient
spinal cord compression or risk of pathological
fracture. Symptomslike pain, los sof function,
bleeding, obstruction may be relieved by appropri-
ately focussed EBR. The modality is particularly
useful for metastases in bone, soft tissue, paraspinal
and pelvic regions. EBR is of little value in common
sites of STS dissemination, such as multiple lung or
liver metastases, pleural effusion or widespread
intraperitoneal disease.
Chemotherapy
Standard dose chemotherapy
It isgenerally accepted that the anthracyclines
(doxorubicin (DOX), epirubicin (EPI) and ifosfa-
mide (IFOS)) are the most active single agents in
adult STS,
28,29 with single agent response rates in
the range 20–30%. Dacarbazine (DTIC) also has
limited activity. Although marginal activity in the
10–15% range hasbeen documented for a large
number of other agentsand s ome have been
incorporated in combination regimens, it is doubtful
whether they contribute anything other than toxicity.
Etoposide is said to be synergistic with IFOS and
this is a well-established combination regimen in
paediatric sarcomas.
30 Etoposide is inactive in adult
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31,32 and it is also unclear from published pilot
studies
33,34 whether the combination ismore active
than IFOS alone.
Despite the extensive literature on a variety of
combination chemotherapy regimens, it is still
difficult to establish the most effective systemic
treatment for advanced STS. Indeed, it can be
questioned whether combination chemotherapy has
any advantages over the sequential use of active
single agents. A meta-analysis
35 of eight RCTs
comparing single agent DOX with 10 DOX-based
combination regimensin 2281 patientss howed only
a non-significant trend for improved response rate
with combination chemotherapy (OR¼0.78, 95%
CI 0.60–1.05, P¼0.10) and no benefit for overall
survival (OR¼0.84, 95% CI 0.67–1.06, P¼0.13).
Considering only the two RCTs that included
combination regimens using optimal standard
doses of DOX and IFOS, an ECOG (Eastern
Cooperative Oncology Group) study
36 showed a
higher response rate of 34% for DOX/IFOS com-
pared with 20% for DOX alone (P¼0.03), whereas
in an EORTC study
37 respective response rates were
23 and 28% for DOX and DOX/IFOS (P not
significant). In neither study was overall survival
different between the arms. Although the addition
of IFOS to DOX/DTIC increased the response rate
(32 vs. 17%, P<0.002) in an Intergroup RCT,
38
it had no impact on survival.
In conclusion, if palliation of symptomatic meta-
static disease is the goal of therapy, this is likely to be
best achieved by sequential single agent therapy.
High dose chemotherapy
Historically myelosuppression, particularly neutro-
penia with the risk of infection, has been dose limiting
for many chemotherapy agentsand combinations .
The widespread availability of hemopoietic growth
factors(granulocyte or granulocyte/macrophage
colony stimulating factors (G-CSF, GM-CSF))
permitsthe exploration of high-dos e chemotherapy.
Thistopic hasrecently been reviewed.
39
(a) Dose escalation of individual active agents. Dose
escalation of DOX and its analogues continues to
be limited by cardiotoxicity, despite the introduction
of dexrazoxane.
40,41 Liposomal encapsulation of
anthracyclinesmay alter the s pectrum of toxicity,
but their benefit in termsof prevention of cardiotoxi-
city remainsto be proven. In an EORTC (European
Organization for Research and Treatment of Cancer)
RCT
42 liposomal doxorubicin had equivalent efficacy
to DOX, with a lower incidence of febrile neutro-
penia, but more skin toxicity and hypersensitivity.
Whether such a toxicity profile will permit dose
escalation is uncertain at present.
In STS most attention has been paid to dose
escalation of IFOS. Doses of 12g/m
2 without, and
14–18g/m
2 with growth factor support, seem
achievable, but are often associated with high
incidencesof nephro- and neurotoxicity. In thes e
exploratory studies, often conducted in patients
who have received previouschemotherapy that
might have included standard dose IFOS, response
rateshave varied s ubs tantially from 0 to 46%.
43–47
Differencesin patient populationsbetween s tudies
probably account for the discrepancies. Whether
intravenousintermittent daily bolusor continuous
infusion is the better schedule
44,49 hasnot been
resolved, although a recent EORTC study found no
difference in response rates, progression-free and
overall survival between these two methods of
administration of IFOS 9g/m
2.
50 Prolonged infusion
over 21 days may be a less toxic way to administer
high dose IFOS.
51
(b) Dose escalated combination chemotherapy. Several
groups have conducted phase I and II studies of
high-dose anthracycline/IFOS combinations with or
without DTIC, with response rates ranging from 31
to 67%.
52–64 Toxicitieshave been s evere, particularly
thrombocytopenia, and the neuro- and nephrotoxi-
cities of IFOS. At these doses neutropenic fevers are
common, for growth factorsdo not completely
protect against myelosuppression.
Preliminary results on response rates in two RCTs,
evaluating moderate dose escalation supported by
G-CSF, are not encouraging. A RCT
65 comparing
standard dose DOX/IFOS (previously used by
EORTC) with the same regimen with a 50% dose
escalation of DOX, showed similar response rates,
20 vs. 21% in 314 patients. Bui et al.
66 compared
standard dose MAID with the same regimen dose
escalated 25%, and showed respective response rates
of 37% in 76 patientsand 43% in 72 patients(not
significantly different). Doses of DOX (75mg/m
2)
and IFOS (5g/m
2) administered in these studies
were lower than in many of the high-dose phase I and
II studies, but such dose-intensified treatments may
only be tolerated by a select patient population (age
<65, XRT to <20% marrow, performance status
0–1, no prior chemotherapy) asacknowledged by
Patel et al.
58 Thistopic isreviewed in a s eriesof
papers ‘‘Should high-dose chemotherapy be used in
the treatment of soft tissue sarcoma?’’ providing
pro, contra and arbiter views.
67
(c) High-dose chemotherapy with autologous marrow
(ABM) or stem cell (SC) support. Data on very high-
dose chemotherapy with ABM/SC support are even
more sparse.
68–79 Although these studies document
the feasibility of a variety of high-dose protocols, the
small numbers of patients in each precludes any
accurate assessment of benefits. Negative results for
high-dose chemotherapy and ABM/SC in two large
RCTs
80,81 in metastatic breast cancer do not augur
well for success in metastatic STS.
48 V. H. C. BramwellIn conclusion, high-dose regimens should be
evaluated against standard treatment in RCT that
include quality of life and economic endpoints.
Currently their use for disease palliation outside a
clinical trial setting is not recommended. Their
potential value asadjuvant treatment, or for the
aggressive management of young patients with
metastatic disease merits further exploration.
Novel/investigational treatments
Expanding knowledge of both cancer cell biology
and the process of metastasis has led to the
development of a range of novel compounds.
Drugs that interrupt cell signalling pathways,
82
modulate drug resistance mechanisms, or interfere
with malignant cell invasion (matrix metalloprotei-
nase inhibitors) and/or angiogenesis,
83 are now
available. Specific vaccinesand immune modulators
are under development.
84
For example, troglitazone activatesthe ligand for
the PPARg nuclear receptor and stimulates terminal
differentiation in pre-adipocytes.
85,86 Demetri et al.
87
reported preliminary results of a phase II trial of this
drug in 34 patients with liposarcoma. Biopsy samples
were taken before and after treatment. Five of seven
patientswith biops y evaluable myxoid/round cell
liposarcoma exhibited lineage appropriate differen-
tiation of the liposarcoma cells.
STS show high primary drug resistance. Poor
efficacy/toxicity ratiosmay account for negative
RCTsevaluating amphotericin B
88 and amiodar-
one.
89 The reduced toxicity of a new generation of
compoundsallowsthem to be tes ted at an appro-
priate dose. Preliminary results of the drug Biricodar
(VX-710) that reverses two important mechanisms of
resistance, MDR and MRP, are promising. Added to
DOX, Biricodar induced 2PR in 15 non-GIST STS
proven to be resistant to DOX alone.
90 Mechanisms
of resistance for a variety of chemotherapy agents
used in the treatment of STS are reviewed by Colvin
et al.
91 STS are often characterised by acquired
changeswhich affect G1 checkpoint control (e.g.
Cdk over-expression) resulting in unregulated pro-
gression through the cell cycle. This provides the
rationale for a Canadian Sarcoma Group study of
flavopiridol, an agent that hasinhibitory effectson
several cyclin-dependent kinases.
92 Ecteinascidin
743 (ET-743), a novel minor groove DNA-binding
agent specific to guanine–cytosine-rich regions, is
showing promising activity in early phase II studies
in STS.
93–95
The most exciting development in systemic treat-
ment for mesenchymal tumours is the striking
activity of STI-571 in advanced and metastatic
GIST. STI-571 isa rationally des igned drug which
selectively inhibits BCR-ABL, KIT and PDGFR
tyrosine kinases, and has established activity in
chronic myeloid leukaemia. GIST are characterised
by expression of the proto-oncogene c-kit and
contain gain of function mutationsleading to
ligand-independent activation. In European
96 and
US
97 phase II studies, a majority of patients with
GIST (who are notoriously resistant to conventional
chemotherapy) have responded to daily oral doses of
600–800mg of STI-571. Preliminary data from a
randomised phase III trial (Intergroup S0033)
evaluating two dose levels (400 vs. 800mg/day) in
patients with unresectable or metastatic GIST
98
documents response rates of 43 and 41%, respec-
tively, with no differencesin progres s ion-free (80 and
82%) and overall survival (91 and 92%) at 6 months.
It is anticipated that final response rates will be
higher.
Chemotherapy may occasionally be indicated for
desmoid tumours causing major symptoms and/or
invading vital structures. However, Ballo et al.
1
reported 5-, 10- and 15-year survival rates of 96,
92 and 87%, respectively, for patients treated by
surgical resection with or without radiotherapy, and
Mitchell et al.
99 make a convincing case that these
tumourscan have prolonged periodsof s table
disease. This characteristic makes interpretation of
response to treatment difficult. There are data from
several sources documenting responses to low-dose,
well-tolerated chemotherapy comprising weekly vin-
blastine and methotrexate,
100–102 and more aggres-
sive chemotherapy of the type used for STS
103,104
should rarely be necessary unless low-dose che-
motherapy has failed and/or disease threatens life or
major organ function. Using immunohistochemistry
and qualitative real-time polymerase chain reaction
analysis, Mace et al.
105 demonstrated consistent
positivity for KIT and PDGFR a and b in nine
desmoid tumour specimens. Two patients were
treated with imatinib and demonstrated clinical and
radiological responses ongoing at 9 and 11 months.
An additional case report
106 documentsa res pons e
to imatinib in dermatofibrosarcoma protuberans.
Clearly further study is warranted in this difficult
disease.
Multimodality treatment
An argument in favour of high-dose combination
chemotherapy intended to maximise response is that
combined with aggressive surgery it may lead to cure
of metastatic STS. Small prospective studies have
been performed,
107,108 and in some patients there
has been long-term control of disease. However,
metastatic STS can have an extremely variable
natural history, and in the absence of appropriate
randomised control groups and long-term follow-up
it isdifficult to determine overall benefit.
An interesting retrospective analysis of 38 patients
achieving complete CR in Scandinavian Sarcoma
Group studies
109 showed that those achieving CR by
chemotherapy alone had a longer median survival
Management of advanced adult soft tissue sarcoma 49(23 months) than those who were converted to CR
by surgery following chemotherapy (10 months).
A good histological response to chemotherapy
(defined in this study as no or few small areas of
viable tumour) predicted a good outcome in patients
subjected to surgery. It is conceivable that intrinsic
drug sensitivity, rather than specific regimen or dose,
isthe main determinant of a good outcome for
patientsreceiving chemotherapy.
Innovative routesfor the delivery of chemotherapy
in combined modality therapy include isolated lung
perfusion for unresectable lung metastases,
110 hepa-
tic chemoembolisation
111 and intraperitoneal treat-
ment.
112,113 These procedures require a high level
of technical expertise and should be done only in the
context of a prospective clinical trial.
Factors predicting benefit of chemotherapy
The most reliable data on prognostic factors for
patientsreceiving chemotherapy for metas tatic
STS isfrom an analys isof an EORTC databas e,
comprising 2185 patients receiving first line anthra-
cycline-based chemotherapy in seven RCT spanning
a period of 20 years.
114 Overall survival time (median
51 weeks) and response to chemotherapy (26%
CRþPR) were used as the two major endpoints for
a prognostic factor analysis. By multivariate analysis
(Cox model) good performance status (P<0.0001),
absence of liver metastases (P¼0.001), low histo-
pathological grade (P¼0.0004) and young age
(P¼0.0045) were favourable factorsfor s urvival.
Absence of liver metastases (P<0.0001), young age
(P¼0.0024), high histopathological grade (P¼
0.0051) and liposarcoma (P¼0.0065) were favour-
able factors for response. By univariate analysis,
synovial sarcoma subtype predicted a favourable
response. However, this subtype was strongly corre-
lated with young age. Thismay account for anecdotal
information from Rosen’s group that synovial sarco-
masres pond particularly well to IFOS,
115 asthe age
range in this study was 14–39 years. Blay et al.
116
analysed a subset of the same database, comprising
2187 patientsreceiving DOX chemotherapy in RCT
between 1976 and 1990, and described features
characterising long-term (5-year) survivors. There
were 66 of 1888 patientsalive at 5 years , who were
more frequently: female (69 vs. 51%), had grade I
tumours (35 vs. 11%), and had PS 0 (63 vs. 41%).
Although CR on DOX wasa major parameter
correlated with 5-year survival, with 21% (17/81)
being alive at 5 years, the fact that 17 of 323 patients
(5%) with PR, 17 of 658 patients(3%) with SD and
three of 630 (0.5%) with PD were also alive at 5 years
illustrates the heterogeneity of outcome for patients
with advanced STS. In a third analysis of the same
database by Reichardt et al,
117 the presence of locally
recurrent disease together with metastases predicted
for a low response rate and poor survival.
Active treatment versus best supportive care:
decision process
For patients with non-resectable local or metastatic
STS, the relative meritsof active treatment with
radiotherapy and/or chemotherapy versus sympto-
matic measures for individual patients may be
assessed using the following criteria:
(a) Isthere a remote chance of long-term control or
cure with active treatment?
(b) Is the disease symptomatic, or are serious
complicationsimminent?
(c) Isthisthe optimum time to intervene?
(d) Isit likely that the benefit/toxicity ratio of active
treatment will be favourable (i.e. istreatment
likely to improve quality of life)?
(e) How will co-morbidities(e.g. age, performance
status, tumour burden, other illnesses) influence
treatment outcomes?
Summary of management
Locoregional disease
Management of patientswith inoperable local STS is
challenging. Site of disease, the severity of symp-
toms, speed of tumour growth, age, performance
status and comorbid diseases are factors that should
be considered in formulating a treatment plan. This
will be influenced by the preferencesof patient and
family. Long-term control ismos t likely to be
achieved by a combination of chemotherapy with
such local measures (surgery, radiotherapy) that are
permitted by anatomic limitationsand previous
radical treatments. Speed of tumour growth is an
important consideration — even advanced STS can
be remarkably heterogeneousin thisres pect. For
slow-growing STS, causing few symptoms, the best
quality of life may be achieved by judiciousobs erva-
tion and occasional symptomatic measures.
Metastatic disease
Metastases at certain sites may be amenable to
removal, with good palliative benefit and occasional
cure. These sites may include lung, liver, abdominal
cavity, lymph nodesand brain. Factorsthat, in
general, will predict a favourable outcome include
control of the primary tumour, one or small numbers
of metastases in one site which are fully resectable,
slow tumour growth (often indicated by a long
disease-free interval from primary resection to
development of metastases  2 years) and good
performance status/lack of comorbid diseases.
In patients with metastases that are completely
resectable the role of chemotherapy remains
controversial, and surgery alone is a reasonable first
approach. Chemotherapy or, at selected sites, radio-
therapy, may be added if resection is incomplete,
50 V. H. C. Bramwellbut the benefit of such treatments is not established.
Alternatively, if disease is surgically accessible,
complete resection may prolong CR and PR
achieved with chemotherapy. If combined modality
treatment isplanned, initial chemotherapy permitsa
determination of chemosensitivity.
Disease progression in patients with GIST can be
highly variable, and it isworth following as ympto-
matic patientsto determine the rate of growth of
metastases before considering systemic treatment.
Imatinib isnow available for palliative treatment of
patients with symptomatic progressive metastatic
GIST, and is being tested in the adjuvant setting.
In contrast to ASTS, histological subtypes of
sarcomas commonly seen in the paediatric age
group (embryonal rhabdomyosarcomas, primitive
neuroectodermal tumours) may also be chemosensi-
tive in adult patients, and such patients should
receiveintensive multiagentchemotherapy.However,
results for adult patients are generally poorer than
for children. Esnaola et al.
118 reported outcomesof
treatment for 39 adults, median age 26 (16–82)
years, with rhabdomyosarcoma (embryonal, seven;
alveolar, 22; pleomorphic, 10; not specified, five)
treated at their institutions between 1973 and 1996.
Twenty-six had locoregional disease and 13 meta-
static disease at presentation. Thirty-seven patients
received chemotherapy, with high overall (72%) and
complete response (41%) rates. Nevertheless, 5- and
10-year overall survival rates were low, 31 and 27%,
respectively. Patients with locoregional disease had a
44% 5-year survival rate, but there were no survivors
among patients with metastatic disease. Data from
another small series of juvenile-type STS in adults
suggests that the long-term outlook is poorer than
in children.
119
For patientswith metas tatic STS the ultimate
goalsof chemotherapy will determine whether or not
it should be given and if so, its timing and type. The
exact role and benefitsof chemotherapy hasbeen a
controversial subject over many years.
120–123 Young
fit patients may be willing to risk substantial toxicity
for a chance to maximise response to chemotherapy
with the possibility of long-term control and a remote
chance of cure. Early treatment with an aggressive
high-dose combination chemotherapy regimen 
growth factors may be most appropriate for these
patients. However, many patients with STS are
elderly with other health problems, and palliation
of symptoms is the main objective. In this situation,
the ideal time to initiate chemotherapy iswhen the
patient is starting to get symptoms or has disease
likely to cause major complications leading to a
deterioration in performance status. A reasonable
option for these patients is sequential single agents,
e.g, DOX followed by IFOS at the time of relapse.
If there is clearly measurable disease at the time of
initiation of chemotherapy it should be possible to
determine response within two to three cycles and
terminate chemotherapy if it isineffective. Res pons e
is unlikely if there is clear progression of disease in
the first two cycles, but stabilisation of disease after
previous rapid progression is an indication for
continued therapy.
Because of the high rate of intrinsic drug resis-
tance, and the limited number of effective drugs,
further salvage chemotherapy after first line failure
of combination chemotherapy is rarely successful.
For patients in relapse after previous response,
higher-dose IFOS might be an option. If phase I
or II trialsare available locally, thes e are oppor-
tunitiesfor patientsactively s eeking further
treatment.
Conclusions
There ismuch to offer patientswith advanced STS
in the form of specific anticancer and supportive
therapies. Nevertheless, there is much to learn and a
great need for well-designed studies, particularly
large phase III RCTs addressing important ques-
tions. What are the questions? In the context of this
chapter a non-exhaustive list would be:
1. What isthe role of newer techniques /energiesof
radiotherapy in controlling inoperable, recurrent
and/or metastatic STS?
2. Is surgical resection of metastases beneficial in
STS, and might this vary with sites of metastases?
3. Is ‘high-dose’ better than ‘standard-dose’ chemo-
therapy? Thiswould include inves tigation of the
feasibility/safety of such treatments in different
patient populationswith STS.
4. Do the benefitsof chemotherapy vary according
to histological subtype?
5. Isit feas ible to target chemotherapy to different
histological subtypes/grades/other tumour char-
acteristics according to mechanisms of drug
action?
6. Doeschemotherapy before or after s urgery for
metastases improve survival?
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